c61190sc13da2.htm

0001214659-09-001500.txt : 20090611 0001214659-09-001500.hdr.sgml : 20090611 20090611162056 ACCESSION NUMBER: 0001214659-09-001500 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20090611 DATE AS OF CHANGE: 20090611 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HARENBURG THOMAS A CENTRAL INDEX KEY: 0001030512 FILING VALUES: FORM TYPE: SC 13D/A SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOANALYTICAL SYSTEMS INC CENTRAL INDEX KEY: 0000720154 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 351345024 STATE OF INCORPORATION: IN FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-52991 FILM NUMBER: 09887219 BUSINESS ADDRESS: STREET 1: 2701 KENT AVE CITY: WEST LAFAYETT STATE: IN ZIP: 47906-1382 BUSINESS PHONE: 3174634527 MAIL ADDRESS: STREET 1: 2701 KENT AVENUE CITY: WEST LAFAYETTE STATE: IN ZIP: 47906-1382 SC 13D/A 1 c61190sc13da2.htm AMENDMENT NO. 2 c61190sc13da2.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

(Amendment No. 2)

Under the Securities Exchange Act of 1934

BIOANALYTICAL SYSTEMS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

09058M-10-3

(CUSIP Number)

THOMAS A HARENBURG

206 N MAIN ST. PO BOX 1069

OSHKOSH WI 54903

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

June 11, 2009

(Date of Event which Requires

Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box x

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D/A

CUSIP No.		09058M-10-3			Page 2 of 5 Pages
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
	THOMAS A HARENBURG
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)					(a)	o
						(b)	o
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	INVESTMENT FUNDS
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)						o
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	US
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			7	SOLE VOTING POWER
				155,307
			8	SHARED VOTING POWER
				121,460
			9	SOLE DISPOSITIVE POWER
				155,307
			10	SHARED DISPOSITIVE POWER
				121,460
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	276,767
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES						o
	(SEE INSTRUCTIONS)
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	5.63%
14	TYPE OF REPORTING PERSON
	INDIVIDUAL INVESTOR

Page 3 of 5

Item 1. Security and Issuer.

This statement on Schedule 13D (“Schedule 13D”) relates to 276,767 shares of common stock, of BIOANALYTICAL SYSTEMS AN INDIANA corporation (the “Issuer”), whose principal executive offices are located at 2701 KENT AVE., WEST LAFAYETTE, IN 47906.

Item 2. Identity and Background.

(a) This Schedule 13D is filed by THOMAS A HARENBURG who is referred to herein as the “Reporting Person.”

(b) The Reporting Person’s business address is 206 N MAIN ST., OSHKOSH, WI 54901.

(d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, the Reporting Person has not been a party to any other civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) United States of America.

Item 3. Source and Amount of Funds or Other Consideration.

INVESTMENT FUNDS

Item 4. Purpose of Transaction.

REQUESTING BOARD REPRESENTATION 1 OF 5 EXISTING SEATS

Page 4 of 5

Item 5. Interest in Securities of the Issuer.

(a) The Reporting Person may be deemed to be the beneficial owner of 276,767 shares of Common Stock. Such 276,767 shares represent approximately 5.63% of the outstanding shares of Common Stock.

(b) The Reporting Person has the sole power to vote or to direct the vote or to dispose or to direct the disposition of 155,307 shares.

(d) Not applicable.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Not applicable.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.2 - Letter to the Board of Directors of Bioanalytical Systems

Page 5 of 5

Signatures

After reasonable inquiry and to the best of the knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: June 11, 2009


		/s/ THOMAS A HARENBURG
		THOMAS A HARENBURG

EX-99.2 2 ex99_2.htm ex99_2.htm

Exhibit 99.2

Carl M. Hennig, Inc.
Investment Securities ● Main and Otter ● P.O. Box 1069 ● Oshkosh, WI 54903-1069 ● 920-231-6630 ● Fax 920-231-1883

June 11, 2009

To The Board of Directors of Bioanalytical Systems,

After over two years of failed attempts to turn Bioanalytical Systems, Inc. around, I feel the need to change the current board is now, and I am; therefore, backing the Kissinger proposals for the board of John Landis, Joseph Broecker, and Candice Kissinger. This is in addition to my request to have Jerome G. Marchant serve as my representative on the board.

Due to the urgency of this matter, the time is now. I would like to see this acted upon by June 30th.

Respectfully Submitted,

/s/ Thomas A. Harenburg